Buscar

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Leer más About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

Wearing headphones or earbuds is a daily activity for many of us. Listening to music, podcasts, meetings, phone calls; there are endless reasons to stick them in or on your ears. However, if your ears start to feel plugged, full; or you feel dizzy, lightheaded or hear ringing in your ears; you may be experiencing ear wax build up where your ear canals become blocked and affect your hearing. If you’ve tried to clean your ears (please don’t use Q-Tips®), but still have symptoms, pain, or hearing loss, it’s time to see your physician, nurse practitioner, physician assistant or visit Renown Urgent Care. “Ear wax isn’t dirty. It’s normal,” says Ryan Bristol, APRN, Advanced Practitioner of Nursing at Renown Urgent Care. “Ears are self-cleaning miracles, and naturally clean themselves with the help of jaw movement and skin migration. However, wearing headphones or earbuds for hours blocks earwax from naturally draining from the ear. Additionally, the dirt and bacteria that these headphones often carry can cause an infection on their own, and earwax buildup can trap dirt in the ear and block the canal completely. The snug fit of headphones can create a conducive environment for the accumulation of ear wax. It's crucial for individuals to be mindful of this and take necessary precautions to prevent complications." “Individuals experiencing symptoms such as ear pain, decreased hearing, or a sensation of fullness in the ears are encouraged to seek evaluation and treatment at their nearest urgent care facility,” says Rahul Mediwala, MD, CEO of Renown Medical Group. “By addressing ear wax build-up promptly, individuals can mitigate the risk of complications and maintain optimal ear health. Fortunately, prompt, pain-free and effective treatment is available at Renown Urgent Care. We offer professional ear wax removal procedures performed by trained staff, providing relief to those experiencing discomfort or hearing impairment due to excessive ear wax build-up.” The experts at Renown Health gave us some background. What is ear wax and why is it healthy? Ear wax is a protective substance called sebum made of fat, skin cells and sweat. Ear wax is produced by glands in the ear canal. It helps protect the ear from germs and dirt and prevents the sensitive skin of the ear canal from becoming irritated. It is normal and healthy to have a thin lining of ear wax on the canal. Ear wax will sometimes accumulate and move to the outer ear canal, where it would typically fall out or be wiped away. This is also normal. When should I seek care? An ear canal has too much wax if the ear feels plugged or hearing is affected. The accumulation of wax happens very gradually, so ears do not necessarily feel waxy. The problem is usually noticed because of changes in hearing. Over the counter remedies may offer relief. However, in some cases, the earwax has built up or become impacted, and ears need to be treated. What is the treatment? At Renown Urgent Care, we offer professional ear wax removal procedures performed by trained staff, providing relief to those experiencing discomfort or hearing impairment due to excessive ear wax build-up. Wax is flushed from the ear canal using a syringe filled with warm water and saline or diluted hydrogen peroxide. Most patients find the procedure is fast, pain free and effective. How can I prevent earwax buildup from headphones and ear buds? Most people who wear headphones or use earbuds occasionally or intermittently don’t have difficulties with excessive ear wax. Wax accumulation also depends on the size of the ear canals and the productivity of the oil glands in the ear canal. You can choose to use over the ear headphones. If you prefer to use in-ear headphones, the best modes of excess ear wax prevention are to: Clean headphones and earbuds regularly with a cloth or disinfectant wipes; Avoid sharing headphones or earbuds with other people; Take breaks from headphones and earbuds so ears can breathe and get back to normal; Pay attention to your ear health. Should we talk about Q-tips? Yes! Q-tips (and similar products) are rarely helpful for managing ear wax. The cotton on the end of the Q-tip is usually unable to pull the wax out of the canal. Worse, they can push the wax deep inside the ear canal, and it can end up impacted. Where should I seek care? Individuals experiencing symptoms such as ear pain, decreased hearing, or a sensation of fullness in the ears are encouraged to seek evaluation and treatment at a medical facility. By addressing ear wax build-up promptly, individuals can mitigate the risk of complications and maintain optimal ear health. Renown Urgent Care sees patients 365 days a year for medical concerns that are urgent but not life-threatening at many locations across northern Nevada. Reserve con antelación un lugar en una de nuestras diez ubicaciones de Urgent Care. If you do not see time slots that work for you, you can still go to any location that has "walk-ins available" listed. For more information, or to book an appointment, go to renown.org/Health-Services/Urgent-Care. Renown Health is the region’s locally governed, not-for-profit integrated health care network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,200 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health.

Leer más About Let Those Ears Breathe! Increased Headphone and Ear Bud Use Leads to Ear Wax Build Up; Renown Urgent Cares Offer Relief

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. En virtud de los términos del acuerdo de colaboración y licencia, Gilead proporcionará fondos al Renown IHI para secuenciar y analizar el ADN de 15,000 personas que viven con EHNA o con enfermedad de hígado graso no alcohólico (EHGNA), así como de una cohorte de control de 40,000 personas en el estado de Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene 40,000 participantes. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. La EHNA es más frecuente en personas con ciertas afecciones, que incluyen obesidad y diabetes tipo 2. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead opera en más de 35 países alrededor del mundo, con sede central en Foster City, California. Para obtener más información sobre Gilead Sciences, visite el sitio web de la empresa en www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Mediante el uso de su ensayo Exome+™ de propiedad exclusiva, un exoma de tipo panel mejorado con más de 300,000 regiones no codificantes informativas, Helix ofrece a los sistemas de salud una solución escalable que permite el descubrimiento de información genética médicamente relevante y que potencialmente puede salvar vidas. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Obtenga más información en www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Estos y otros riesgos se describen en detalle en el Informe Trimestral de Gilead en el Formulario 10-Q para el trimestre que finalizó el 31 de marzo de 2019, presentado ante la Comisión de Bolsa y Valores de los EE. UU. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Leer más About Gilead Sciences y el Renown Institute for Health Innovation anuncian una colaboración estratégica para promover la comprensión de la esteatohepatitis no alcohólica (EHNA)

Three-day medical education conference advances research, education, prevention and treatment. Physicians and medical professionals from throughout the Mountain West will soon be convening in Lake Tahoe to explore emerging treatments, the most recent advances and new clinical guidelines for the diagnosis, treatment and prevention of cardiovascular disease, diabetes mellitus, stroke and heart disease. Organizada por el Institute for Heart & Vascular Health de Renown y la Academia de Médicos de Familia de Nevada, la conferencia “Tendencias en medicina cardiovascular”, de tres días de duración, reunirá a expertos nacionales para explorar los desafíos y las soluciones con respecto a las enfermedades cardiovasculares, la principal causa de muerte en el mundo, que se calcula que se cobra 17.9 millones de vidas cada año. "Our mission is to advance health in America. As Nevada's first integrated health system, with our University of Nevada, Reno School of Medicine affiliation, we are advancing health and health care through world-class medical education, clinical research and patient care for our community, our state and our nation," says Anthony D. Slonim, MD, DrPH, President & CEO, Renown Health. "And, we have so much work to do. En 2019, el 9.5 % de los nevadenses informó haber recibido un diagnóstico de angina o enfermedad coronaria por parte de un profesional de la salud, lo cual se encuentra significativamente por encima del promedio nacional del 8.4 %. As public health and health care providers, we can do more to encourage people to adopt healthy lifestyle habits to keep their heart healthy and help prevent heart disease through the Healthy Nevada Project®, where people can understand their genetic risks at no-cost." "The driving force behind this collaborative event is the shared missions of all our organizations, across the country, to advance progress in cardiovascular research, education, prevention and treatment," says Jayson Morgan, MD, FACC, Director Cardiovascular Services at Renown. "We will be joined by colleagues from Johns Hopkins, Cedars-Sinai, Scripps, University of New Mexico Health Sciences, University of Utah, Medical College of Wisconsin, the Metabolic Institute of America and locally- with experts from Renown's Institute for Heart & Vascular Health/UNR Med, St. Mary's and Barton Health - to discuss contemporary trends in providing excellent cardiovascular care and prevention." New research will be presented each day, including: “Vaping and Electronic Cigarettes – The Hidden Epidemic: What the Clinician Needs to Know” Michael J. Blaha, MD, MPH, FACC, Professor of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Director of Clinical Research, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD “Optimizing Glycemic Control in the Inpatient Setting” Kendall M. Rogers, MD, CPE, FACP, SFHM, Professor, Department of Internal Medicine, University of New Mexico School of Medicine, Chief, Division of Hospital Medicine, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM “Perioperative Medicine Update”                                                                                                                                                                                             Barbara A. Slawski, MD, MS, SFHM Professor of Medicine & Orthopaedic Surgery, Chief, Section of Hospital Medicine, Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI “Understanding hATTR Amyloidosis: Clinical Presentation and Treatment Landscape (Comprender la amiloidosis hATTR: presentación clínica y panorama de tratamiento) Jignesh K. Patel, MD; PhD; FACC; FRCP; FAST; FAHA; profesora clínica de Medicina; directora médica del Programa de trasplante cardíaco; directora del programa Cardiac Amyloid; directora de Investigación de Trasplante Cardíaco, Cedars-Sinai Medical Center, Los Ángeles, CA. “Coronary Artery Calcium in 2021: Guideline-Endorsed and Ready for Prime Time” (Calcio en las arterias coronarias en 2021: avalado por las directrices y listo para recibir atención) “The Evolving Landscape of Obesity Management – A Update” (La evolución del panorama de la gestión de la obesidad: actualización de ) Ken Fujioka, MD; director del Center for Weight Management; director del Nutrition and Metabolic Research Center, Scripps Clinic Departamento de Diabetes y Endocrinología, San Diego, CA. “The Evolving Panscape of Obesity Management – A 2021 Update” (La evolución del panorama de la gestión de la obesidad: actualización de ) Ken Fujioka, MD; director del Center for Weight Management; director del Nutrition and Metabolic Research Center, Scripps Clinic Departamento de Diabetes y Endocrinología, San Diego, CA. “Management of Atrial Fibrillation: Where We Are; Where We Are Headed” Matthew A. Cain, MD, Electrophysiologist, Renown Institute for Heart & Vascular Health, Renown Medical Group, Reno, NV "The Story of a Murmur” Abhilash Akinapelli, MD, Cardiac Valve & TAVR Program Director, Renown Institute for Heart & Vascular Health, Renown Medical Group, Reno, NV "Update on the Cardiovascular Effects of COVID-19” Siddharth Singh, MD, Assistant Director, Echo Fellowship Training Program, Smidt Heart Institute, Cedars-Sinai, Los Angeles, CA “Antibiotic Stewardship: How to Improve Our Prescribing for Now and Later”                                                                                                                            Valerie M. Vaughn, MD, MSc, FACP, FHM, Assistant Professor, Instructional Track Director of Hospital Medicine Research, Division of General Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT "Emerging Trends in the Clinical Management of VTE”                                                                                                                                                                Victor F. Tapson, MD, FCCP, FRCP, Director, Clinical Research for the Women’s Guild Lung Institute, Director, Venous Thromboembolism & Pulmonary Vascular Disease Research Program, Associate Director, Pulmonary and Critical Care Division, Cedars-Sinai Medical Center, Los Angeles, CA “Contemporary Approach to the Management of Diabetes as a Cardiovascular Disease”                                                                                               Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, Medical Director & Principal Investigator, Metabolic Institute of America, Tarzana, CA The Arthur J Lurie, MD Memorial Dinner and Keynote Presentation, sponsored by the charitable Renown Foundation and the Lurie Family, is an evening ceremony to honor and memorialize the devotion and innovation of the lake Dr. Arthur J. Lurie, who personified humanitarian, medical and community service. Dr. Lurie devoted modernized heart surgery and was steadfast in his commitment to introduce new and groundbreaking techniques cardiovascular techniques to Nevada. Promovió e inspiró investigaciones y avances que cambiaron vidas en la cirugía cardíaca, así como en la investigación del cáncer, hasta su fallecimiento en 1996. Se invita a los profesionales de la medicina a asistir a la 31.ª Conferencia anual sobre Tendencias en medicina cardiovascular, que tendrá lugar en el Resort at Squaw Creek, en Olympic Valley, California, del viernes, 5 de noviembre al domingo, 7 de noviembre de 2021. Quienes deseen registrarse u obtener más información pueden visitar www.renown.org/trends. The clinical team at Renown Institute for Heart and Vascular Health is the recipient of a number of national awards for outstanding clinical care and service, including: En los rankings de Mejores Hospitales de U.S. News and World Report de 2021, Renown Regional Medical Center ocupa el primer puesto en el estado de Nevada para 2021. Ningún otro hospital en Nevada obtuvo el reconocimiento de U.S. News. Renown Regional Medical Center is High Performing, its highest rating possible, for Heart Failure and Chronic Obstructive Pulmonary Disease. El Renown Regional recibió el premio America’s 100 Best Hospitals for Critical Care Award (2021) del Colegio Estadounidense de Cardiología por la obtención de resultados clínicos superiores en el tratamiento de embolia pulmonar, insuficiencia del sistema respiratorio, sepsis y emergencias diabéticas. El Renown Regional también ganó el Pulmonary Care Excellence Award™ (2021) por la obtención de resultados superiores. Designated Level II Trauma Center. For the 30th year, Renown Regional Medical Center is northern Nevada's only designated level II trauma center. Renown Regional awarded The Get with the Guidelines - Heart Failure Gold Plus Quality Achievement award for continually ensuring heart failure patients receive the most appropriate treatment according to nationally recognized, research-based guidelines, as well as AHA's mission: Lifeline Gold Receiving honor for the treatment of patients who suffer severe heart attacks. American College of Cardiology's NCDR Chest Pain-MI Registry Platinum Performance Achievement Award. El Renown Regional Medical Center es uno de los únicos 225 hospitales de todo el país en recibir el premio. The award recognizes Renown's success in implementing a higher standard of care for heart attack patients and signifies that Renown has reached an aggressive goal of treating these patients to standard levels of care as outlined by the American College of Cardiology/American Heart Association clinical guidelines and recommendations.  To make an appointment with a provider at Renown's Institute for Heart and Vascular Health, request that your primary care provider make a referral. For more information on Renown's Institute for Heart and Vascular Health, visit renown.org/Health-Services/Heart-Care.     Acerca de Renown Health Renown Health es una red de atención médica integrada de administración local y sin fines de lucro que brinda servicios al norte de Nevada, Lake Tahoe y el noreste de California. En los rankings de mejores hospitales de U.S. News y World Report, Renown Regional Medical Center ocupa el primer puesto en el estado de Nevada. Renown tiene una larga trayectoria y un compromiso de larga data con la mejora de la atención y la salud de nuestra comunidad. Visite renown.org para obtener más información.

Leer más About Expertos líderes se reúnen en Tahoe para centrarse en los avances científicos y la prevención de las enfermedades cardiovasculares, la primera causa de muerte a nivel mundial.

Presented by the Desert Research Institute and Renown Health, DANA will help people learn more about the Healthy Nevada Project® and their own unique, genetic health traits What is the Healthy Nevada Project®? What are the benefits of joining this research study? How can I find out if I carry genes for health risks like heart disease, hereditary breast and ovarian cancer syndrome and Lynch syndrome? What if a holographic avatar, powered by artificial intelligence (AI), could answer all these questions and more? DANA has all the answers, she is a virtual assistant with “DNA” in her name, presented by the Renown Institute for Health Innovation (Renown IHI), a collaboration between Renown Health and the Desert Research Institute (DRI). This life-sized, holographic avatar will greet individuals outside Renown Regional Medical Center’s Sierra Café, and talk to them about the Healthy Nevada Project, the world’s largest community-based genetic population health study. Los representantes de medios de comunicación están invitados a reunirse con DANA esta mañana, desde las 10 a.m. hasta el mediodía. Responda a este correo electrónico o llame al (775) 691-7308 para coordinar una reunión. “Unfortunately, Nevada ranks among the lowest in the nation for health outcomes—and we are working to change that,” said Anthony Slonim, M.D., D.Ph., president and CEO of Renown Health and president of Renown Institute for Health Innovation. “Through the Healthy Nevada Project® , our goal is to offer genetic testing to every Nevadan interested in learning more about their health and genetic profile. Thanks to this advanced technology, DANA will offer people a personalized explanation of the Project, and help them take the next step to better understand their health, and their health risks, so they can modify their behavior and ultimately, live a healthier, happier life.” Con más de 51,000 participantes del estudio inscritos hasta la fecha, el Healthy Nevada Project® se considera el estudio genético de más rápida inscripción del país. The Project is also the first of its kind to return clinical results to study volunteers, which means participants can learn their genetic risks tied to heart disease and certain cancers, as well as lifestyle changes that could potentially help reduce their risk and prevent disease. Furthermore, participants can choose to share their information with their medical provider to improve and enhance their medical care. “We are always happy to engage with our study participants and look forward to having them meet and engage with DANA,” said Joseph Grzymski, Ph.D., research professor at DRI, principal investigator of the Healthy Nevada Project® and chief scientific officer for Renown Health. “At a time of physical distancing and limiting human contact where possible, using tools like an avatar and AI are important for communicating, whether it be for genetics, vaccinations or other important health information.” Visitors can interact with DANA through a touch screen (cleaned and sanitized after every encounter) to learn more about the study, enter their contact information and schedule an appointment to join the free genetics study or receive more information about their test results. Kiosk visitors are asked to maintain physical distance guidelines and use the hand sanitizer and Sani Wipes available next to the kiosk.     Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org.

Leer más About Presentación de Dana, el nuevo quiosco holográfico tamaño real del Renown Institute for Health Innovations

El enfoque basado en la comunidad del Healthy Nevada Project revela que hasta un 90 % de los riesgos de padecer afecciones genéticas de Nivel 1 de los CDC no se detecta cuando se usan pautas de atención clínica. In a new study published today in the journal Nature Medicine, researchers behind the Healthy Nevada Project® suggest that community-based genetic screening has the potential to efficiently identify individuals who may be at increased risk for three common inherited genetic conditions known to cause several forms of cancer and increased risk for heart disease or stroke. En 2018, el Healthy Nevada Project® (el mayor estudio de salud poblacional basado en la comunidad que combina datos genéticos, clínicos, ambientales y sociales) comenzó a notificarles a los participantes del estudio que habían dado su consentimiento sobre ciertas variantes genéticas que los predisponían a padecer las afecciones genéticas de Nivel 1 de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC). The study focused on identifying carriers of these conditions, which include Hereditary Breast and Ovarian Cancer, Lynch Syndrome, and Familial Hypercholesterolemia, because they are the most common conditions and early detection and treatment could significantly lower morbidity and mortality. Los resultados iniciales de casi 27,000 participantes del estudio mostraron que el 90 % de los portadores de las afecciones genéticas de Nivel 1 de los CDC no había sido previamente identificado en un entorno clínico. The authors conclude that population genetic screening would identify at-risk carriers not identified during routine care. “Our first goal was to deliver actionable health data back to the participants of the study and understand whether or not broad population screening of CDC Tier 1 genomic conditions was a practical tool to identify at-risk individuals,” explained Joseph Grzymski, Ph.D., the principal investigator of the Healthy Nevada Project®, a research professor at the Desert Research Institute (DRI), chief scientific officer for Renown Health and lead author of the study. “Now, two years into doing that, it is clear that the clinical guidelines for detecting risk in individuals are too narrow and miss too many at risk individuals.” Del grupo de 26,906 participantes del Healthy Nevada Project® que el equipo de investigación de Grzymski estudió, 358 (el 1.33 %) eran portadores de afecciones de Nivel 1 de los CDC. Sin embargo, solo el 25 % de esas personas cumplían las pautas clínicas para realizarse exámenes de detección genética. Además, más del 20 % de los portadores ya tenía un diagnóstico de enfermedad relacionada con la afección genética subyacente. “We’re at a point now where it’s possible to do clinical-grade genetic screening at population-scale,” added James Lu, M.D. Ph.D., co-founder and chief scientific officer of Helix and senior co-author of the study. “What this study demonstrates is the potential impact of doing so. By making genetic screening available more broadly, we can help the millions of Americans who are unaware that they are living at increased risk for highly actionable, genetic conditions take action.” En particular, el estudio descubrió que de los 273 participantes que eran portadores de las afecciones genéticas de Nivel 1 de los CDC y que tenían información de registros clínicos, solo 22 personas mostraron sospechas previas de tener estas afecciones genéticas subyacentes. “For the first time, we are providing information at the individual level so study participants can make lifesaving changes to reduce their risk based on their genetics,” said Anthony Slonim, M.D., Dr.PH., FACHE, president and CEO of Renown Health and co-director of the Project® study. “We’re conducting research on the community level to develop leading-edge research on health determinants for entire neighborhoods, states and eventually, the country. Returning these results allows us to understand the prevalence of genetically programmed diseases and illnesses that we have here in Nevada and ensure we are providing the best prevention and care plans. For the individual, the return of results can be life changing.” According to the CDC, early detection and intervention of the Tier 1 genetic conditions could have a meaningful potential for clinical action ability and a positive impact on public health. El Healthy Nevada Project®, que se lanzó en 2016, ofrece pruebas genéticas gratuitas a todos los residentes de Nevada, mayores de 18 años, interesados en obtener más información sobre su salud y perfil genético. Con más de 50,000 participantes del estudio inscritos en cuatro años, el Healthy Nevada Project® se ha convertido en el estudio genético de más rápida inscripción del mundo. For more about the Healthy Nevada Project® please visit healthynv.org     Renown Institute for Health Innovation is a collaboration between Renown Health – a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute – a recognized world leader in investigating the effects of natural and human induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at Healthynv.org. Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+Ⓡ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research. In response to the COVID-19 public health crisis, Helix has launched a sensitive and scalable end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country. Obtenga más información en www.helix.com.

Leer más About Los exámenes de detección genética poblacionales demuestran que identifican de manera eficiente un aumento en el riesgo de padecer enfermedades hereditarias

Renown Health's Dr. Christopher Rowan recently joined a distinguished panel of experts on the "Game Changers in Medicine" podcast to discuss the science behind the discovery of warfarin. Renown Health Cardiologist Dr. Christopher Rowan was just featured on an episode of Game Changers in Medicine, a groundbreaking medical history podcast from Dramatic Health about some of the world’s most significant medical discoveries. The episode, Warfarin: How a rat poison became one of the world's most widely prescribed drugs, dives into the fascinating history of Warfarin and its life-saving effects on humans.  During the episode, Dr. Rowan, whose research focus is heart disease and atherosclerosis, is joined by experts Kevin Walters, Historian and Strategic Research Coordinator at the Wisconsin Alumni Research Foundation (WARF); and Ramya M. Rajagopalan, Ph.D. of the Institute for Practical Ethics at UC San Diego. Listen to the episode now or download it wherever you listen to podcasts.  History of Warfarin Warfarin prevents blood clots from forming or expanding. The drug is especially important for individuals who have experienced a heart attack or stroke, or are at risk of experiencing either. However, the backstory of the drug is rather fascinating.  Beginning in the 1920s, an unknown disease was killing cattle throughout the U.S. and Canada. Desesperado por encontrar una solución, un granjero condujo 200 millas hasta la University of Wisconsin con una vaca muerta, fardos de heno estropeado y una lata de leche con sangre sin coagular. El hombre se cruzó con un científico, cuyo equipo se propuso determinar el componente hemorrágico del heno estropeado, lo que dio como resultado una serie de descubrimientos médicos que revolucionarían la medicina. Tras aprender más sobre la warfarina y cómo la vitamina K podría revertir sus propiedades anticoagulantes, los médicos recetaron por primera vez la medicina para uso humano en 1954. Probablemente sea muy conocida por salvar al presidente Dwight D. Eisenhower después de que sufrió un ataque cardíaco en 1955. Today, Warfarin continues to saves millions of lives each year. “Before blood thinners like Warfarin, people would experience strokes, blood clots in their lungs, blood clots in their legs, blood clots in their hearts, along with countless other clotting disorders - these conditions likely cutting their lifespans short,” Dr. Rowan said during the podcast. “Warfarin revolutionized the treatment of patients who suffer from heart attacks and strokes, helping them to live normal and healthy lives. The drug changed medicine forever and helped make incredible innovations such as mechanical heart valves a reality.” Interview Opportunity Dr. Rowan is available for interviews to discuss the importance of this unique medical discovery and the positive impact it has on many of the patients he treats every day. Envíe un correo electrónico a news@renown.org o llame al 775-691- 7308 para coordinar una entrevista. Acerca de Renown Health Renown Health es la red de atención médica integrada de propiedad y administración local y sin fines de lucro más grande de la región, que presta servicios en Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project® . Visite renown.org para obtener más información. About Dramatic Health Dramatic Health, a national healthcare video company, is the producer of the six-part podcast series Game Changers in Medicine. The series premiered in July with an episode about Vitamin K and an enterprising Boston house doctor. The August episode showcased the creation of a smallpox vaccine and its parallels to today's urgent search for a COVID-19 vaccine. Game Changers in Medicine se clasificó en el puesto 27 de los podcasts de Apple en la categoría “Ciencias de la vida en los Estados Unidos” de acuerdo con Chartable al 21 de agosto de 2020. Los dos episodios, un resumen de la serie y material adicional sobre la serie de podcasts están disponibles en www.gamechangersinmedicine.com y se puede acceder a estos materiales desde la plataforma que utilice para escuchar podcasts.

Leer más About Renown Cardiologist Shares Insight on Warfarin

Pictured left to right: Erin VanKirk, MSN, RN, Renown Health Director of Nursing Education; Mitch Krebs, Program Director at Helmsley Charitable Trust; Dr. Graf, Renown Health CEO; Greg Walaitis Renown Health Chief Development Officer. Renown Health will use the grant to build the Helmsley Simulation and Innovation Center to improve the health system’s training abilities The Leona M. and Harry B. Helmsley Charitable Trust has granted $3.1 million to Renown Health for construction of a new simulation and innovation center that will greatly expand the health system’s ability to train healthcare providers throughout northern Nevada. The new center will be named the Helmsley Simulation and Innovation Center. Expected to open in April 2023, the center will feature three simulated patient rooms, classroom space, computer labs and a conference center, allowing trainers to run current and future healthcare professionals through real-life acute, outpatient, telemedicine and specialty care scenarios. The new center will let Renown Health train substantially more nurses, physicians, community clinical partners, medical students and rural providers while improving medical and nursing expertise to support staff throughout northern Nevada. “The Helmsley Charitable Trust is excited to fund this new simulation center, which will provide healthcare professionals across rural Nevada with state-of-the-art training in a variety of situations they’ll encounter,” said Walter Panzirer, a trustee of the Helmsley Charitable Trust. “The project fits with our goal to level the playing field by giving rural residents access to top-notch healthcare, regardless of their ZIP code.” “Simulation education has become standard practice for many of our healthcare personnel,” said Erin Van Kirk MSN, RN, Director of Nursing Education. “This lab will provide expanded opportunities in a controlled setting where physicians, nurses, and students can gain valuable experience in providing the best care possible.” Renown Health has outgrown its current simulation lab, which opened in 2016 in Renown Regional Medical Center. The new, larger, state-of-the-art simulation and innovation center will increase Renown Health’s training capacity from 1,500 to 2,500 each year. The new facility will be equipped with state-of-the-art simulation mannequins and other equipment that includes a telemetry monitor, IV and epidural equipment, a code cart, a defibrillator, a balloon pump, ventilators and a cooling machine. The center will also support Renown Health’s recently established partnership with the University of Nevada, Reno School of Medicine, expanding training modules focused on rural health and virtual care through telemedicine. “The facility will help Renown Health respond to our region’s growing population by allowing us to support the training and competency necessary for our care providers to make a genuine difference in the health and well-being of the people and communities we serve,” said Melodie Osborn, RN, MBA, Chief Nursing Executive at Renown Health. “This generous grant for the new simulation and innovation center from the Helmsley Charitable Trust is truly an investment in the bright future we envision for Renown, our care teams and the community.” Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Visite renown.org para obtener más información. About the Helmsley Charitable Trust The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $3 billion for a wide range of charitable purposes. Helmsley’s Rural Healthcare Program funds innovative projects that use information technologies to connect rural patients to emergency medical care, bring the latest medical therapies to patients in remote areas, and provide state-of-the-art training for rural hospitals and EMS personnel. To date, this program has awarded more than $500 million to organizations and initiatives in the states of North Dakota, South Dakota, Nebraska, Wyoming, Minnesota, Iowa, Montana, and Nevada. For more information, visit helmsleytrust.org.

Leer más About Helmsley Charitable Trust Grants $3.1 Million to Renown Health